Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3724 with GEMOX in Relapsed/Refractory B-Cell NHL
NCT03488251Phase 2Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- Aug 2018
- Primary completion
- Mar 2021
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of MT-3724 in B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), sponsored by Molecular Templates, Inc.. Started Aug 2018; status: terminated.
02
Drugs
MT-3724
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03488251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488251.